Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.04 USD | -2.06% | -12.57% | -36.29% |
01:24pm | Guggenheim Upgrades Amicus Therapeutics to Buy From Neutral With $13 Price Target | MT |
10/05 | UBS Trims Price Target on Amicus Therapeutics to $19 From $20, Keeps Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.29% | 267.76Cr | |
+26.37% | 4.82TCr | |
-1.01% | 4.17TCr | |
+45.09% | 4.1TCr | |
-5.31% | 2.88TCr | |
+9.34% | 2.56TCr | |
-21.69% | 1.9TCr | |
+6.23% | 1.29TCr | |
+26.99% | 1.2TCr | |
-3.38% | 1.18TCr |
- Stock Market
- Equities
- FOLD Stock
- News Amicus Therapeutics, Inc.
- Morgan Stanley Upgrades Amicus Therapeutics to Overweight From Equalweight, Raises Price Target to $20 From $15